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Background: Once-daily low-dose aspirin is routinely used for the prevention of secondary events in cardiovascular
disease (CVD). The routine use of aspirin in primary prevention of CVD is less clear due to a finer balance between
benefits and harms. In addition, the variability in benefit achievable from the prescription of aspirin has led to a growing
interest in considering whether there are more effective aspirin regimens than once-daily dosing or whether
effectiveness is influenced by the time of day aspirin is taken (chronotherapy). The proposed systematic review will
evaluate the evidence on the effects of different aspirin regimens used in terms of number of doses (e.g. split or
alternate dosing) or dosing time of aspirin (e.g. morning versus evening) in primary and secondary prevention of CVD.
Methods/design: Standard systematic review methodology will be employed for study identification, selection and
data extraction. Electronic databases will be searched incorporating terms relating to population and the intervention.
No date or language limitations will apply. Systematic reviews and controlled studies comparing different aspirin
regimens—in terms of frequency or timing—for primary and/or secondary prevention of CVD will be included. No
restrictions on outcome will apply. Quality assessment will be appropriate for each study design. The data will be
tabulated and narratively synthesised. Meta-analysis may be undertaken where clinical and methodological
homogeneity exists.
Discussion: There are a number of published and ongoing primary studies that investigate the cardiovascular
protective effect of different aspirin regimens. However, no systematic review to date has attempted to review the
evidence pertaining to aspirin dosing regimens differing in frequency and/or in timing. The proposed systematic
review will cover both the above questions and could potentially be beneficial for reconsidering the current practice
of managing patients with aspirin in primary care.
Systematic review registration: PROSPERO CRD42014010596
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Cardiovascular disease (CVD) continues to be the leading
clinical and public health problem worldwide, causing
17.5 million deaths each year [1]. Aspirin is one of the
most common, useful and inexpensive antiplatelet drugs
used for the prevention of CVD.
In line with the UK and EU guidelines [2, 3], patients
with established CVD are recommended long-term
treatment with daily low-dose aspirin that effectively
reduces the yearly risk of serious adverse events such as
myocardial infarction, stroke, or vascular death. For
secondary prevention of CVD, the benefits of daily
low-dose aspirin therapy substantially exceed the risks
[4]. There is considerable uncertainty though around
the benefits of aspirin in individuals with no history
of prior CVD but who may be at risk of cardiovascular
events [5]. To that end, health organisations recommend
the use of aspirin for primary prevention of CVD when a
net benefit is present [6]. Indeed, some evidence suggests
a small prophylactic effect from daily low-dose aspirin
in patients with cardiovascular risk factors, but any
potential clinical benefit should be carefully weighed
against a potential increase in the risk of undesirable
effects (e.g. gastrointestinal bleeding and haemorrhagic
stroke) [7, 8].
It is known that aspirin therapy is not equally effective
in all patients, with some experiencing repeat cardio-
vascular events despite aspirin administration. Poor
compliance with the treatment may be one explan-
ation for less effective aspirin therapy [9, 10]. Variable
response to aspirin may also depend on the patient
population studied, patient age, co-morbidities and/or
co-medications, and kinetics of aspirin targets [11, 12].
Recent evidence has suggested that accelerated platelet
function recovery after inhibition with aspirin could be an
additional factor for this observed variability in platelet
responsiveness [13–18].
It has been suggested that altering the standard dosing
regimen of once-daily aspirin (e.g. to twice-daily) or
changing the timing of aspirin intake may confer better
cardiovascular protection in some patient populations.
Chronotherapy, an emerging concept in the field of
therapeutics, is a treatment method in which adminis-
tration of a drug is timed to match the circadian rhythm
of disease in an attempt to optimise the therapeutic
outcome and minimise treatment side effects [19]. The
recommended aspirin regimen is one tablet (75–150 mg)
per day to be taken at least 30 min before breakfast. How-
ever, it is known that the incidence of thromboembolic
events has a peak period during the morning [20]. Taking
aspirin in the morning will result in inhibition of platelet
function occurring within 60 min of ingestion [21] and may
result in highest plasma level of the drug being reached
after the morning peak incidence of cardiovascular events.It has therefore been proposed that evening intake of
aspirin may result in a more protective effect [17, 22].
In addition, the potential merit of a split-dosing regimen
(e.g. twice- versus once-daily) has been reported in patients
with diabetes [17, 23–25] or hypertension [26]. Based on
these studies, it has been suggested that patients with
suboptimal response to aspirin or those where aspirin
treatment appears to have been ineffective may benefit
from this dosing regimen as a result of a greater platelet
inhibition or reduction in blood pressure. In contrast, less
frequent administration of aspirin (e.g. every other day)
could be an alternative regimen in order to minimise
adverse events, such as bleeding, from long-term
treatment, though it is currently not known in which
patient groups this might be beneficial.
Despite the existence of a number of systematic re-
views that focus on the effectiveness of daily low-dose
aspirin in primary and secondary prevention of CVD
[4, 5, 7], a scoping search in MEDLINE and The
Cochrane Library identified no existing systematic reviews
that focus on both frequency of dosing and timing of
aspirin administration. A broad review with some sys-
tematic methodological elements was identified [19],
which covered the chronotherapy (i.e. timing of therapy)
of a range of drugs, including aspirin (searches up to
2011). There were some methodological limitations to this
review, including language and date restrictions and a lack
of quality assessment of included studies. The review
was also not reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. Thus, the robustness of the overall
findings is uncertain. A further systematic review and
meta-analysis from 2011 on timing of administration was
identified [27], however, this appears to be published in
abstract form only, and full details on methodology could
not be ascertained. Scoping searches also indicate that a
number of recent publications that are likely to be
relevant are not included in the above reviews. Thus,
an up-to-date, methodologically robust, systematic re-
view is warranted. The proposed systematic review
will evaluate the evidence on the effects of different
aspirin regimens (in terms of number of doses and/or
timing of aspirin administration) used in primary and
secondary prevention of CVD.
Methods/design
Research questions
The aim is to undertake a systematic review of the
evidence on alternative dosing and timing regimes of
aspirin used in primary and secondary prevention of
CVD. This can be split in two research questions:
 The effect of split daily dosing (e.g. once versus
twice or more) or alternate-day dosing of aspirin
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secondary prevention of CVD, and
 The effect of timing of aspirin intake (e.g. evening
versus morning) on primary and secondary
prevention of CVD
This protocol is registered with PROSPERO (CRD
42014010596) and has been reported here according to
the PRISMA-P guidelines (Additional file 1). The project
was presented to a patient group in order to help inform
the protocol.
Searches
The following sources will be searched for primary
studies:
 Bibliographic databases—MEDLINE, MEDLINE
In Process and EMBASE via Ovid, CINAHL
via EBSCO, and The Cochrane Library
(CDSR, DARE and CENTRAL databases)
 Science Citation Index (Web of Science) for
citation searching
 The ISRCTN database, UKCRN, WHO ICTRP
Portal and ClinicalTrials.gov for ongoing studies
 Specialist abstract and conference proceeding
resources (British Library’s ZETOC and Conference
Proceedings Citation Index (Web of Science))
 Checking of citation lists of included studies and
relevant reviews
 Selected websites of organisations such as the British
Heart Foundation (BHF), the National Institute for
Health and Care Excellence (NICE) and the
American Heart Association (AHA)
A combination of text words and MeSH terms relating
to number of doses and timing of aspirin will be utilised.
Given the variable terminology for these elements, the
search strategies will be broad using a range of terms,
such as once/twice-daily, once/twice a day, alternate-day or
split-dosing, morning/awakening versus evening/bedtime,
time of taking, daily administration, chronopharmacology,
chronoefficacy etc. There will be no restriction on date or
language of publication. A sample search strategy for MED-
LINE is provided in Additional file 2, and this strategy has
been adapted for use in each bibliographic database.
The literature search results will be entered onto
EndNote X7.1 (Thomson Reuters, New York) to facilitate
removal of duplicate records, study selection, recording
decisions and referencing. The study selection process will
be conducted in two stages: (1) title and abstract screening
and (2) full-text reading of potentially relevant studies. At
both stages, two reviewers will independently assess the
studies for inclusion using predetermined eligibility criteria.
Any discrepancies between reviewers will be resolved bydiscussion, and in case of disagreement, a third reviewer
will be involved until consensus is reached. Translation of
non-English language articles will be undertaken if
necessary. The selection process will be illustrated using a
PRISMA study flow chart.
Selection criteria
Study design
A preliminary scoping search suggested that the volume
of primary studies is likely to be small. To this end, any
controlled studies (randomised or non-randomised,
prospective or retrospective, concomitant or historical
control) will be included. Non-controlled studies, single
case reports and narrative reviews will not be considered.
Participants
Participants will be individuals given aspirin for primary
or secondary prevention of cardiovascular events.
Primary prevention includes patients with diabetes,
hypertension or another disease (like atrial fibrillation)
with a potentially high risk for a cardiovascular event to
occur. Secondary prevention includes patients with estab-
lished cardiovascular disease. Patients in an acute setting
where aspirin is administered post-operatively to prevent
thromboembolic events, such as deep vein thrombosis,
pulmonary embolism and embolic stroke, will be con-
sidered but as a distinct group. Studies with mixed
population will be included providing results for a popula-
tion of interest can be extracted. Pregnant women at risk
of developing gestational hypertension or preeclampsia
and studies on healthy volunteers will be excluded.
Observational studies reporting different levels of incidental
or self-selected aspirin use (i.e. not prescribed for primary
or secondary prevention) will also be excluded. There will
be no age restrictions.
Intervention and comparator
Aspirin dosing regimens will include the following:
 Split-dosing: aspirin taken twice or more per day
compared to a regimen with lower frequency
(e.g. once per day)
 Alternate-day dosing: aspirin taken every other day
compared to a more frequent regimen (e.g. every day)
 Different times of the day, e.g. aspirin taken in the
morning compared to the evening
The focus will be on aspirin as the sole antiplatelet
therapy (monotherapy), but studies where same additional
therapies are given in all study arms will also be included
(e.g. dual or triple therapy). Where there is a difference in
both overall dose and number of doses or timing, the
study will be included. However, if the only difference is
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time), the study will be excluded.
Outcomes
There will be no restriction by outcome. Based on scoping
searches, there are likely to be only a small number of
studies reporting clinical and/or patient-related outcomes
of interest. Therefore, surrogate end points will also be
included.
Primary outcomes
 Cardiovascular events (e.g. myocardial infarction,
ischemic stroke, transient ischemic attack composite
outcomes, e.g. MACE (major adverse cardiac events))
 Mortality
 Adverse events (e.g. bleeding)
Secondary outcomes
 Blood pressure
 Platelet function as measured with a platelet
function test
 Compliance
There will be no restriction of length of study or type
of effect measure.
Data extraction
Data extraction will be conducted by one reviewer using a
standardised, piloted data extraction form, with selected
data, particularly relating to quality and outcomes, checked
by a second. Discrepancies will be resolved through
discussion or referral to a third reviewer. The following
information (but not limited to) will be extracted from all
included studies:
 Study characteristics: country of origin, study
design, setting, sample size, length of follow-up
 Population: patient inclusion and exclusion criteria,
co-morbidities, co-medications, platelet kinetics
 Intervention/comparator: dose, timing of dose, number
of doses, patient adherence (how assessed/reported)
 Results: completeness of follow-up, outcome
measures, statistical methods employed, findings,
effect sizes and associated uncertainty
Study authors and researchers may be contacted if
further information is required.
Quality assessment
Assessment of all selected publications for their methodo-
logical quality will be undertaken. Study quality of primary
studies will be assessed using tools specific to each studydesign. The risk of bias tool from the Cochrane Handbook
[28] will be used to assess the internal validity of rando-
mised and non-randomised controlled trials, considering
different types of bias such as selection, performance,
detection, attrition and reporting bias. The quality of each
article will be appraised by two reviewers independently,
and the reasons for their decisions will be recorded.
Disagreements will be resolved by discussion or referral to
a third reviewer. Should relevant cross-over trials be
identified, then additional areas of risk of bias will need to
be assessed, e.g. whether there is a carry-over effect due to
insufficient washout periods between phases, whether only
relevant first period data are available, and comparability of
results with those from parallel-group trials.
For controlled observational studies, the domains in
the risk of bias tool for RCTs will be used as a minimum
quality assessment (regardless of the fact that there is no
randomisation). The most relevant criteria for assessment
are likely to relate to how the groups were selected, differ-
ences in patient characteristics, loss to follow-up, and
biases in outcome assessment and reporting. In addition,
the extent to which confounders have been given adequate
consideration, both in reporting and analysis, will be
examined. For historical control studies, additional factors
to be included are possible changes in the diagnostic
criteria, outcome definitions/measurements and/or differ-
ences in concomitant standards of care over time.
The quality information will be used in the context of
considering the robustness of evidence for each outcome
for each comparison, as well as indicating any common
issues for consideration when designing any new studies.
Analysis
Synthesis of evidence will be undertaken separately for
the different systematic review questions. Narrative syn-
thesis of evidence will be conducted for all included
studies with the extracted data to be tabulated as de-
fined in the data extraction section. It is most likely that
the outcome measures will be expressed as continuous
data (e.g. mean/median or mean difference in blood
pressure or platelet aggregation) or, for cardiovascular
events, as dichotomous data.
Meta-analysis will be conducted where appropriate to
combine data from similar studies. Assessment of clinical
and methodological heterogeneity will be used to deter-
mine whether meta-analysis is appropriate and if so,
whether a fixed effect or random effects model should be
used. Statistical heterogeneity will be measured by using
Higgins and Thompson’s I2 and chi-squared statistics [29].
Evidence from RCTs and other controlled studies will
not be quantitatively combined together, but presented
separately (both on a study and outcome level). Visual
representation of results in forest plots without pooling
may also be considered.
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be grouped according to patient characteristics (e.g. those
taking aspirin for primary or secondary prevention) or
overall dose. The robustness of results to methodological
quality of included studies may be explored in sensitivity
analysis; this will be dependent on sufficient reporting of
quality criteria in order to make an overall assessment
of study quality. The potential for the existence of
publication bias will be assessed via funnel plots if there
are at least 10 studies in a given meta-analysis, and using
the appropriate statistical tests for small study effects
(such as the Peters Test [30]).
Reporting
The Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) framework [31] will
be used to summarily consider inconsistency (or hetero-
geneity) between studies, precision (uncertainty) of re-
sults, likelihood of publication bias and applicability
of results to population(s) of interest. The review and its
findings will be reported in accordance with the PRISMA
guidelines [32].
Discussion
A large number of people take a daily low-dose aspirin
tablet for prophylaxis against prospective or recurrent
cardiovascular events. The benefit seen from such therapy
is however variable between patient groups and indi-
viduals, and it has been proposed that changes to dosing
regimens (frequency or timing of aspirin administration)
may be beneficial to some in terms of improving the
efficacy of aspirin. An up-to-date systematic review of the
evidence on different dosing regimens therefore appears
to be warranted. Results from the review will need to be
interpreted in the context of study quality, documented
adherence of patients to aspirin therapy and relevance of
the outcome measures used in the included studies.
Further, the use of aggregate data (particularly of continu-
ous outcomes) may mean that findings are not necessarily
generalisable to individual patients. Nonetheless, findings
are likely to be important given the large number of
patients on aspirin currently being managed in primary
care. Any gaps in the existing evidence will be highlighted
in order to inform future research directions including
new trials in this area.
Additional files
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Additional file 2: Sample search strategy. Sample search strategy to
identify relevant primary studies in MEDLINE.
Abbreviations
CVD: cardiovascular disease; RCT: randomised controlled trials.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DB, JD, SS and DM developed the methodological strategy of the project.
SB developed the search strategy. DB and JD drafted the manuscript.
ML and JH provided clinical and methodological advice. DF is the principle
investigator. All authors read and approved the final manuscript.
Acknowledgements
This is an independent project funded by the UK NIHR School for Primary
Care Research. The School for Primary Care Research (SPCR) is a partnership
between the Universities of Birmingham, Bristol, Keele, Manchester,
Nottingham, Oxford, Southampton and UCL and is part of the National
Institute for Health Research. The views expressed in this protocol are those
of the authors and not necessarily those of the NHS, the NIHR or the
Department of Health.
Author details
1Public Health, Epidemiology and Biostatistics, School of Health and
Population Sciences, College of Medical and Dental Sciences, University of
Birmingham, Edgbaston, Birmingham B15 2TT, UK. 2NIHR Surgical
Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital
Birmingham, Edgbaston, Birmingham B15 2TH, UK. 3Montreal Heart Institute,
Research Centre, 5000 rue Bélanger, Montréal, QC H1T 1C8, Canada. 4Faculté
de pharmacie, Université de Montreal, C.P. 6128, Succ. Centre-ville, Montreal,
QC H3C 3J7, Canada. 5Primary Care Clinical Sciences, School of Health and
Population Sciences, College of Medical and Dental Sciences, University of
Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Received: 2 April 2015 Accepted: 11 June 2015
References
1. Cardiovascular diseases (CVDs). Fact sheet N°317. Wold Health Organisation.
2015. http://www.who.int/mediacentre/factsheets/fs317/en/.
Accessed 12 March 2015.
2. British Cardiac S, British Hypertension S, Diabetes UK, Heart UK, Primary
Care Cardiovascular S, Stroke A. JBS 2: Joint British Societies’ guidelines on
prevention of cardiovascular disease in clinical practice. Heart.
2005;91 Suppl 5:v1–52.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al.
European Guidelines on cardiovascular disease prevention in clinical
practice (version 2012): The Fifth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of nine societies and by
invited experts). Atherosclerosis. 2012;223(1):1–68.
4. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose
aspirin in the secondary prevention of cardiovascular and cerebrovascular
events. Arch Intern Med. 2002;162(19):2197–202.
5. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al.
Aspirin for prophylactic use in the primary prevention of cardiovascular
disease and cancer: a systematic review and overview of reviews.
Health Technol Assess. 2013;17(43):1–253.
6. Using aspirin for the primary prevention of cardiovascular disease: clinician
fact sheet. Agency of Healthcare Research and Qiality, Rockville, MD. 2009.
http://www.ahrq.gov/professionals/clinicians-providers/resources/
aspprovider.html. Accessed 12 March 2015.
7. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al.
Aspirin for primary prevention of cardiovascular events in people with diabetes:
meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
8. Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J,
Godwin J, et al. Aspirin in the primary and secondary prevention of vascular
disease: collaborative meta-analysis of individual participant data from
randomised trials. Lancet. 2009;373(9678):1849–60.
9. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, et al. Aspirin
noncompliance is the major cause of “aspirin resistance” in patients
undergoing coronary stenting. Am Heart J. 2009;157(5):889–93.
10. Dawson J, Quinn T, Rafferty M, Higgins P, Ray G, Lees KR, et al. Aspirin
resistance and compliance with therapy. Cardiovasc Ther. 2011;29(5):301–7.
Bem et al. Systematic Reviews  (2015) 4:88 Page 6 of 611. Rocca B, Dragani A, Pagliaccia F. Identifying determinants of variability to
tailor aspirin therapy. Expert Rev Cardiovasc Ther. 2013;11(3):365–79.
12. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets.
2012;23(7):526–36.
13. Lordkipanidze M, Harrison P. Aspirin twice a day keeps new COX-1 at bay.
J Thromb Haemost. 2012;10(7):1217–9.
14. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al.
24-hour time-dependent aspirin efficacy in patients with stable coronary
artery disease. Thromb Haemost. 2011;105(2):336–44.
15. Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG.
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary
artery disease. Int J Cardiol. 2011;150(1):39–44.
16. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and
time-dependent antiplatelet effects of aspirin. Thromb Haemost.
2006;95(4):652–8.
17. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The
recovery of platelet cyclooxygenase activity explains interindividual
variability in responsiveness to low-dose aspirin in patients with and
without diabetes. J Thromb Haemost. 2012;10(7):1220–30.
18. Wurtz M, Hvas AM, Jensen LO, Kaltoft AK, Tilsted HH, Kristensen SD, et al.
24-hour antiplatelet effect of aspirin in patients with previous definite stent
thrombosis. Int J Cardiol. 2014;175(2):274–9.
19. Kaur G, Phillips C, Wong K, Saini B. Timing is important in medication
administration: a timely review of chronotherapy research. Int J Clin Pharm.
2013;35(3):344–58.
20. Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian
rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151–66.
21. Awtry EH, Loscalzo J. Aspirin Circulation. 2000;101(10):1206–18.
22. Kriszbacher I, Ajtay Z, Koppan M, Bodis J. Can the time of taking aspirin
influence the frequency of cardiovascular events? Am J Cardiol.
2005;96(4):608–10.
23. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily
dosing of aspirin improves platelet inhibition in whole blood in patients
with type 2 diabetes mellitus and micro- or macrovascular complications.
Thromb Haemost. 2011;106(3):491–9.
24. Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S,
et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients
with coronary artery disease. Am Heart J. 2012;164(4):600–6.
25. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al.
Pharmacodynamic effects of different aspirin dosing regimens in type 2
diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv.
2011;4(2):180–7.
26. Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Rodriguez M, et al.
Differing administration time-dependent effects of aspirin on blood pressure
in dipper and non-dipper hypertensives. Hypertension. 2005;46(4):1060–8.
27. Ruan Y. Effect of administration of low-dose aspirin before bedtime on
blood pressure in hypertensive patients: A meta-analysis. Int J Cardiol.
2011;152:S85–6.
28. Higgins JPT, Green S. Cochrane Collaboration. Cochrane handbook for
systematic reviews of interventions, Cochrane book series. Wiley-Blackwell:
Chichester, England, Hoboken, NJ; 2008.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21(11):1539–58.
30. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two
methods to detect publication bias in meta-analysis. J Am Med Assoc.
2006;295(6):676–80.
31. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al.
GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol.
2011;64(12):1311–6.
32. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
Preferred reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
